Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 81 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical StudyStatus unknownNCT02702323Phase 2/3
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsCompletedNCT02700568Phase 2
- Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy SubjectsCompletedNCT02699710Phase 1
- A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 2
- Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With RegorafenibCompletedNCT02699073Phase 2
- Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric CancerStatus unknownNCT02697838Phase 2
- Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse PsoriasisCompletedNCT02695940Phase 2
- Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung CancerStatus unknownNCT02695550Phase 1
- A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male ParticipantsCompletedNCT02692677Phase 1
- Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1
- Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid TumorsCompletedNCT02691793Phase 4
- Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid TumorsWithdrawnNCT02691780Not applicable
- Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid TumorsCompletedNCT02691767Not applicable
- A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02691299Phase 3
- Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia PatientsStatus unknownNCT02690922Phase 4
- Combination of PCI-32765 With Obinutuzumab in Untreated Follicular LymphomaStatus unknownNCT02689869Phase 2
- A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] FruquintinibCompletedNCT02689752Phase 1
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2
- Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid TumorsWithdrawnNCT02689336Phase 2
- Study to Assess Various Sunitinib Schedules in Renal Cell CarcinomaStatus unknownNCT02689167Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
- Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 MutationTerminatedNCT02688907Phase 2
- Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous LeukemiaStatus unknownNCT02687425Phase 2
- Imatinib as Pre-operative Anti-Colon Cancer Targeted TherapyTerminatedNCT02685046Phase 2
- Bioavailability Study Of PF-06651600 In Healthy SubjectsCompletedNCT02684760Phase 1
- Study of Apatinib in Metastatic Esophageal CancerStatus unknownNCT02683655Phase 2
- Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLActive, not recruitingNCT02682641Phase 2
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
- Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaWithdrawnNCT02680951Phase 1
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsCompletedNCT02675491Phase 1
- Phase 1 Study of QuizartinibCompletedNCT02675478Phase 1
- A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid TumorsWithdrawnNCT02674555Phase 1
- A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 1
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
- Phase II Trial GA101 Inbrutinib B CLLCompletedNCT02666898Phase 2
- Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) PatientsStatus unknownNCT02665910Phase 1
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand EczemaCompletedNCT02664805Phase 2
- A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon CancerTerminatedNCT02664077Phase 3
- Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
- Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02659241Early Phase 1
- SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsCompletedNCT02657122Phase 1
- Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
- Hematopoietic Stem Cell Transplant Survivors StudyCompletedNCT02652052Phase 1
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/2
- Study of Metatinib Tromethamine TabletStatus unknownNCT02650375Phase 1
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Phase 2
- Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
- Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaCompletedNCT02645864Phase 1
- Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF)Status unknownNCT02645656Phase 2
- Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesTerminatedNCT02638909Phase 2
- Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTCompletedNCT02638766Phase 2
- Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyCompletedNCT02638467Phase 2
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy AdultsCompletedNCT02638116Phase 1
- A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenActive, not recruitingNCT02637687Phase 1/2
- Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation StudyCompletedNCT02636426Phase 1
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
- Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal CancerWithdrawnNCT02630420Phase 1
- Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02629848Phase 3
- Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02629809Phase 2
- Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNACompletedNCT02629523Phase 2
- Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
- A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationTerminatedNCT02626754Phase 2
- Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene AmplificationCompletedNCT02626364Phase 2
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid TumorsCompletedNCT02626234Phase 1
- Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCCompletedNCT02625168Phase 2
- A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic CarcinomaCompletedNCT02623127Phase 2
- Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS LymphomaStatus unknownNCT02623010Phase 2
- Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerStatus unknownNCT02619435Phase 2
- Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and PharmacodynamicsCompletedNCT02619162Phase 1
- Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1
- Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedNCT02616055Phase 2
- Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaCompletedNCT02614495Phase 2
- Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum MalariaCompletedNCT02614404Phase 1
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedNCT02612558Phase 2
- Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.WithdrawnNCT02611908Phase 1
- Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell TransplantCompletedNCT02611063Phase 1
- Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsCompletedNCT02610361Phase 1
- Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.CompletedNCT02610075Phase 1
- ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic TherapyCompletedNCT02609958Phase 2
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedNCT02608411Phase 2
- A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaTerminatedNCT02608125Phase 1
- Regorafenib in GIST With Secondary C-KIT Exon 17 MutationCompletedNCT02606097Phase 2
- Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS MetastasisCompletedNCT02605746Early Phase 1
- Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal CancerTerminatedNCT02605044Phase 3
- Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal FunctionCompletedNCT02603497Phase 1
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
- Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorTerminatedNCT02601274Phase 1
- Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorCompletedNCT02601248Phase 1
- Bioequivalence Study of Sorafenib Tablet and NexavarCompletedNCT02599337Phase 1
- Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
- Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With CancerCompletedNCT02598726Phase 1
- Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)CompletedNCT02597322Phase 2
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade PineoblastomaCompletedNCT02596828Phase 2